A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis

Study acronym: AID-HD
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Apr 1, 2027 → May 1, 2027
See other at-risk trials from Imperial College London

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 9 more changesShow less
    • Start date changed from estimate of Apr 1, 2026 to Sep 1, 2026
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion pushed from Apr 1, 2027 to May 1, 2027
    • Study completion pushed from Apr 1, 2027 to Dec 1, 2027
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 9 of 10 entries
    • Site details revised at 4 of 4 sites
    • Collaborators: details revised at 2 of 5 entries
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney failure inject themselves with insulin and do finger-prick blood glucose tests. Managing diabetes in people with advanced kidney disease is challenging, with fluctuating glucose levels and an increased risk of unsafe low glucose levels. We now have continuous glucose monitors (CGM), which allow people to monitor glucose without painful fingerprick tests. CGM can be combined with insulin pumps to create automated insulin delivery systems (AID) that automatically deliver insulin to control glucose levels. AID systems are currently used in people with type 1 diabetes, but they are not used in people with type 2 diabetes. There is little information on how these systems might help people with diabetes and advanced kidney failure, and on dialysis. This study will investigate whether automated insulin delivery can improve glucose levels and quality of life in people with type 2 diabetes treated with more than one insulin injection with advanced kidney failure and undergoing regular haemodialysis treatment. This study will be conducted in four UK centres and will be of a parallel design. We estimate that the trial will require 84 participants to be recruited, and 76 participants to be randomised. We aim for 64 participants across both groups to complete the trial. Participants will wear a glucose sensor at the start. In random order, half will be randomised to AID treatment while the other half will continue usual care augmented with continuous glucose monitoring. The duration of each treatment stage is 12 weeks. The study will last about 18 weeks for each participant. We will compare the glucose levels in the AID group with the usual care group to see if there is a difference. Questionnaires and interviews will help us understand participants' experiences. We will carefully monitor the safety of the participants.
Trial Details
NCT Number NCT07422532
Lead Sponsor Imperial College London
Collaborators: Guy's and St Thomas' NHS Foundation Trust, Manchester University NHS Foundation Trust, University Hospitals of Derby and Burton NHS Foundation Trust, King's College London, University of Nottingham
Conditions
(from sponsor)		 Type 2 Diabetes, Chronic Kidney Disease 5D
Related terms Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov